2 Information about pegcetacoplan

Marketing authorisation indication

2.1 Pegcetacoplan (Aspaveli, Swedish Orphan Biovitrum) is indicated 'in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who are anaemic after treatment with a C5 inhibitor for at least 3 months'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics.


2.3 The list price of pegcetacoplan is £3,100.00 for a 1,080‑mg vial (excluding VAT; confirmed by company). The company has a commercial arrangement (simple discount patient access scheme). This makes pegcetacoplan available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)